Lundbeck preps for war against generic drugmakers in US
Lundbeck is facing a patent dispute concerning its second-best selling drug, schizophrenia treatment Rexulti, against companies wanting to reproduce generic versions. CEO Deborah Dunsire will sound the charge this summer.
by BENJAMIN WERNER CHRISTENSEN, translated by daniel pedersen
Pharmaceutical firm Lundbeck is arming itself for battle with several generic drugmakers wanting to produce generic versions of schizophrenia treatment Rexulti before its patent expires.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Lundbeck's Northera took massive dive in 2021
For subscribers
